Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 May;61(5):810-4.
doi: 10.1002/pbc.24892. Epub 2013 Dec 19.

Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma

Robert S Nickel  1 , Frank Keller, John Bergsagel, Todd Cooper, Marla Daves, Himalee Sabnis, Glen Lew
Affiliations
Comparative Study

Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma

Robert S Nickel et al. Pediatr Blood Cancer. 2014 May.

Abstract

Background: Daunorubicin, a component of the four-drug induction chemotherapy regimen for de novo pediatric high-risk acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy), was unavailable in 2011 due to a national drug shortage. During this time, our institution substituted mitoxantrone 6.25 mg/m(2) for daunorubicin 25 mg/m(2) on induction Days 1, 8, 15, and 22. While mitoxantrone has been shown to be effective for relapsed ALL, it has not been studied in de novo pediatric ALL/LLy.

Procedure: We conducted a retrospective cohort study of newly diagnosed patients with ALL or LLy at our institution 1/2009-4/2013 to compare induction toxicity and response of patients treated with mitoxantrone versus daunorubicin.

Results: Eleven patients received mitoxantrone, 121 patients received daunorubicin. Induction toxicities including deaths, intensive care unit admissions, fever, bacteremia, and invasive fungal disease were similar for the two groups. Mean number of days hospitalized during induction was also similar (mitoxantrone 9.7 days vs. daunorubicin 11.2 days, P = 0.60). Minimal residual disease prevalence at the end of induction was not significantly different (mitoxantrone 33.3% vs. daunorubicin 23.0%, P = 0.44). The only significant difference between the groups was that a higher proportion of patients who received mitoxantrone had consolidation delayed due to myelosuppression (mitoxantrone 30.0% vs. daunorubicin 6.0%, P = 0.03).

Conclusion: Induction toxicity and response for new ALL/LLy patients treated with mitoxantrone in place of daunorubicin were similar to the toxicity and response seen with conventional daunorubicin. Mitoxantrone is a reasonable replacement for daunorubicin in times of drug shortage.

Keywords: ALL; chemotherapy; drug shortage; induction; mitoxantrone; pediatric oncology.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Nothing to declare.

References

    1. Sandberg J, Howsden FL, DiMarco A, et al. Comparison of the antileukemic effect in mice of adramycin with daunomycin. Cancer Chemother Rep. 1970;54:1–7. - PubMed
    1. Schwartz HS, Grindey GB. Adriamycin and daunorubicin: A comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 1973;33:1837–1844. - PubMed
    1. Buick RN, Messner HA, Till JE, et al. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man. J Natl Cancer Inst. 1979;62:249–255. - PubMed
    1. Wang JJ, Chervinsky DS, Rosen JM, et al. Comparative biochemical studies of adriamycin and daunomycin in leukemic cells. Cancer Res. 1972;32:511–515. - PubMed
    1. Kaspers GL, Veerman AJ, Pieters R, et al. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia. 1994;8:24–29. - PubMed

Publication types

MeSH terms